PATENT CLAIM ANALYSIS

Application Number: 15873416
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-12
Patent Classification: ["514", "001100"]

Abstract:
The disclosure provides compositions and methods for counteracting the effects of direct activated Factor X (FXa) inhibitors in a subject by administering a variant of FXa.

Claim (Index 2):
The method of  claim 1 , wherein reversal of the anticoagulant effect of the direct Factor Xa inhibitor results in a therapeutic effect selected from the group consisting of: reducing or preventing bleeding in a subject, increasing the amount of thrombin in a subject, decreasing clotting time in a subject, and effecting the urgent reversal of acquired coagulopathy due to FXa inhibition therapy in a subject with acute major bleeding.

Metadata:
- Claim Count in Document: 21.0
- Percentile: 86.0
- Lexical Diversity: 1.11538
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12616735', '13414499', '13889014', '12239651', '13591098']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8241380667225537
- 35 USC 102 Novelty (BERT): 0.5188409121636506
- Combined Prediction Score: 0.7936083512666634
- Mean Citation Score: 318.84791800000005
- Max Citation Score: 322.3307200000001
- Similarity Product: 232.3906366515542

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test